Kalderos’ enhanced Commercial Discount Monitoring solution enables manufacturers to create a data-driven strategy around their commercial contracts and reduce exposure to the revenue leakage caused by duplicate discounts and ineligible rebates. Learn more: https://t.co/ISYA1WQRrz
Do you feel you have a clear and unified view of your gross to net? Kalderos has the industry expertise and the tech-enabled platform to limit revenue leakage. Hear from our experts and see our products in action at the GTN Summit in Philadelphia: https://t.co/F4nFjObjIt
Accuracy matters in calculating gross to net. Kalderos will be onsite at GTN Summit to show how platform technology delivers dependable drug discount data to help your team.
Schedule time to connect 1:1 at GTN: https://t.co/F4nFjObjIt
The Kalderos team can’t wait to connect with you in Philadelphia!
👋 Visit our booth in the Exhibit Hall.
🍸 Join us for two nights of Kalderos-sponsored happy hours.
🗓️ Schedule a 1:1 meeting with us in Philly!
Make your plans for GTN now: https://t.co/F4nFjObjIt
Get clarity on the complex intersection between 340B drug discounts and commercial rebates. Our latest video shows how Kalderos Commercial Discount Monitoring allows manufacturers to know the true impact of their commercial contracts. https://t.co/r5uCWWhUR0
Have you signed up for our webinar yet? We’ll be sharing everything you need to know about our upgraded Commercial Discount Monitoring solution, so grab some leftover Halloween candy and join us on November 1! 🍭 https://t.co/SNhtoOuhzb
Today, Kalderos was announced as the winner of a 2023 Public Relations & Marketing Excellence Award for External Campaign of the Year for our 2023 annual report. You can view and download our 2023 annual report here: https://t.co/7muxcwgRtX
Join us for our November 1 webinar where we’ll share how an enhanced data analytics solution can transform your hand at the negotiating table. Sign up here: https://t.co/SNhtoOuPoJ
340B discounted purchases reached $53.7 billion last year. As the 340B Drug Pricing Program grows, manufacturers can minimize duplicate discounts between 340B and commercial rebates by negotiating better contracts. Learn how at our Oct. 18 webinar: https://t.co/XXDkp4XvNL
In our upcoming webinar, @JeremyGDocken and Rob Philo will discuss the #340B Drug Pricing Program and its intersection with #CommercialContracts. Join us Oct. 18 👉 https://t.co/XXDkp4XvNL
Industry-changing drug pricing regulations were in the spotlight at @InformaConnect’s #MDRPSummit in Chicago last month. Check out the Kalderos blog to see our recap on MDRP Summit’s biggest themes and takeaways. https://t.co/86bN1JM9nJ
With Halloween creeping up, our email newsletter Sightlines is looking at the regulatory changes that might be “scaring” some drug pricing stakeholders. https://t.co/cCWeEE09jI
Get all the industry insights you need this spooky season. Subscribe today: https://t.co/khAmk564Qk
Teamwork makes the dream work. 🤝 Today, we’re sharing the story of a manufacturer that collaborated with Kalderos and covered entities to resolve disputes. Read about how Kalderos and Company V tackled the complex dispute process together: https://t.co/OigyVsOhmu
In our upcoming webinar, Kalderos experts Micah Litow and Sarah Braunstein will discuss the power data has to revolutionize the negotiation process for drug manufacturers. Reserve your spot: https://t.co/SNhtoOuhzb
#CommercialContracting
Commercial contracts between manufacturers and PBMs are famously complex. Commercial Discount Monitoring makes it easier to track contract performance and give manufacturer teams accurate financial reporting. Learn more: https://t.co/ISYA1WQRrz
Commercial Discount Monitoring breaks down contract performance into easy-to-read analytics and dashboards so that manufacturers can inform their contract negotiations with PBMs and identify which contracts are causing revenue leakage. Learn more: https://t.co/ISYA1WQRrz
Discover how technology and Kalderos’ provider network came together to define a big win for a manufacturer. Our latest impact study reveals how Company D resolved a challenge in a high-population state and recovered lost revenue.
Read the study here: https://t.co/eeLozfAer7
Last fall, Company M sought to uncover significant savings from duplicate discounts before the end of the year. In this impact study, we share how we fast-tracked the identification of millions of dollars in noncompliance for the manufacturer. 👉 https://t.co/v31UQfW9nk
Today, Kalderos announced the appointment of longtime healthcare executive Angie Franks as CEO. Franks brings more than 30 years of successful leadership in the healthcare space to lead Kalderos as the company scales its growth. Read the #PressRelease: https://t.co/LI7S8zBUpN